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Abstract 
In the field of vascular gene therapy, targeting systems are promising advancements to improve 
site-specificity of gene delivery. Here, we studied whether incorporation of magnetic nanoparticles 
(MNP) with different magnetic properties into ultrasound sensitive microbubbles may represent an 
efficient way to enable gene targeting in the vascular system after systemic application. Thus, we 
associated novel silicon oxide-coated magnetic nanoparticle containing microbubbles (SO-Mag MMB) 
with lentiviral particles carrying therapeutic genes and determined their physico-chemical as well as 
biological properties compared to MMB coated with polyethylenimine-coated magnetic nanoparticles 
(PEI-Mag MMB). While there were no differences between both MMB types concerning size and 
lentivirus binding, SO-Mag MMB exhibited superior characteristics regarding magnetic moment, 
magnetizability as well as transduction efficiency under static and flow conditions in vitro. Focal 
disruption of lentiviral SO-Mag MMB by ultrasound within isolated vessels exposed to an external 
magnetic field decisively improved localized VEGF expression in aortic endothelium ex vivo and 
enhanced the angiogenic response. Using the same system in vivo, we achieved a highly effective, 
site-specific lentiviral transgene expression in microvessels of the mouse dorsal skin after arterial 
injection. Thus, we established a novel lentiviral MMB technique, which has great potential towards 
site-directed vascular gene therapy. 
Key words: lentiviral gene delivery, magnetic targeting, ultrasound, magnetic microbubbles, VEGF, endothelial 
cells. 
Introduction 
Gene therapy constitutes a promising way to 
specifically modulate signalling pathways and 
vascular physiological responses in both research and 
medical therapy. Regarding the vasculature, 
therapeutic options comprise local treatment of 
ischemia and tumors or organ specific therapy for 
treatment of diabetic retinopathy, to mention a few. 









combines high efficiency and site-specificity following 
intravascular application, is still not available. 
Although the vascular system represents an ideal 
route to deliver therapeutic genes, it is associated with 
systemic distribution and thus non-specific delivery 
of the therapeutic vectors resulting in undesired 
side-effects. Furthermore, biological interactions and 
clearance mechanisms contribute to low gene transfer 
efficiency. Therefore, the application of a carrier 
system capable of improving circulation time in 
combination with specific targeting of the carriers is 
an essential prerequisite for the development of safe 
and efficient gene therapy. Microbubbles (MB) have 
been applied as contrast agent in diagnostic 
ultrasound imaging since three decades 1. Due to their 
unique physico-chemical properties, they are in 
addition used as carriers for biomaterials2,3. The 
gas-filled MB not only allow for controlled and 
localized substance release following local sonication, 
but in addition feature high shape flexibility 
important for the passage through the 
microcirculation in order to decrease clearance of the 
bound substance3,4. However, systemic distribution 
and hence dilution of the MB strongly hampers the 
benefits given by this approach. Therefore, targeting 
mechanisms combining local MB disruption with 
site-specific MB trapping are under intense 
investigations5, 6. One such approach is the coating of 
MB with magnetic nanoparticles (MNP). The resulting 
magnetic microbubbles (MMB) represent an 
innovative and unique gene carrier system enabling 
localized magnetic accumulation of genetic vectors at 
the site of magnetic field (MF) exposure with 
simultaneous vector release and gene transfer 
induced by sonication. In previous work from our 
group we used MNP for targeted transfer of 
oligonucleotides to primary endothelial cells7,8 and 
recently we generated MMB and successfully proved 
their functionality as guidable carrier system for 
pDNA in vivo9. To further improve gene transfer 
efficiency and transgene expression we established 
lentiviral MMB in a previous in vitro study10. 
Although we could prove the feasibility of this 
approach, further optimization of the lentiviral MMB 
technique was shown to be necessary, particularly 
with regard to higher magnetizability to allow for 
successful therapeutic application in vivo. 
Vascular endothelial growth factor (VEGF) is 
considered a therapeutic gene, since it is the most 
potent angiogenic factor with unique actions on 
vascular endothelium11. Besides its important 
physiological role during embryonic development 
and wound healing, it is substantially involved in 
processes regulating adaptive angiogenic responses to 
ischemia and the development of diabetic retinopathy 
and tumor vascularization11. Hence, VEGF has been 
used as a therapeutic target either to promote 
vascularization by its induction12, 13 or to impair vessel 
growth by its inhibition14. An intravascular targeting 
strategy, such as the lentiviral MMB technique, may 
constitute a valuable tool to achieve tissue specific 
angiogenic therapy by targeted gene delivery of 
VEGF.  
In this study, we thus evaluated a new type of 
lentiviral MMB containing silicon oxide-coated MNP 
(SO-Mag) with enhanced performance compared to 
our former established PEI-Mag MMB9,10 in terms of 
physico-chemical properties and gene transfer 
efficiency under static as well as flow conditions. 
Furthermore, we aimed to study whether our 
targeting system would be efficient to locally deliver 
genes to aortic endothelium ex vivo and to the 
microcirculation of mice in vivo upon systemic 
application. 
Results 
Characterization of lentiviral SO-Mag and 
PEI-Mag magnetic nanoparticle-coated 
microbubbles. 
Magnetic microbubbles were generated by 
coating lipid microbubbles with SO-Mag magnetic 
nanoparticles. The physico-chemical properties of 
these MMB, important for successful targeting in vivo, 
were determined and compared to microbubbles 
coated with PEI-Mag magnetic nanoparticles9,10. As 
shown in Table 1, the mean diameter of the MMB 
increased after integration of SO-Mag MNP and 
association of lentivirus reduced the diameter of the 
MMB compared to naked MB (*p≤0.05, n=3). 
However, no difference between PEI-Mag and 
SO-Mag MMB could be detected (Table 1; *p≤0.05, 
n=3). Despite the fact that SO-Mag and PEI-Mag MNP 
possess opposed ζ potentials (-16.1 ± 0.6 mV and +14.7 
± 1.2 mV, respectively) the resulting MMB types both 
exhibit a positive ζ potential. Calculations of the 
average number of MNP embedded in one MMB 
revealed that lentiviral SO-Mag MMB contain 
significantly more MNP compared to lentiviral 
PEI-Mag MMB (Table 1; *p≤0.05, n=3). To prove the 
ability of the SO-Mag MMB to adequately bind 
lentivirus, fluorescently labelled lentiviral particles 
(pCHIV.eGFP) were incubated with the MMB. Flow 
cytometry analysis revealed a complete association 
between MMB and pCHIV.eGFP lentiviral particles. 
However, no difference in lentivirus binding between 
SO-Mag MMB and PEI-Mag MMB was detected (Figs. 
1a and b; *p≤0.05, n=4). To further assess the 
lentivirus binding capacity of MMB and their 
magnetizability, MMB coated with a GFP-expressing 





lentivirus were separated from the solution by 
application of a MF. The resulting concentrated MMB 
and the MMB-free supernatant were separately 
applied to primary human umbilical vein endothelial 
cells (HUVEC) following simultaneous US and MF 
exposure (Fig. 1c). The low GFP expression in cells 
exposed to MMB-free supernatants clearly 
demonstrated the almost complete association of 
lentivirus from the solution to both MMB 
compositions. However, if the magnetically 
concentrated MMB were targeted to cells, SO-Mag 
MMB yielded a significantly higher transduction 
efficiency compared to PEI-Mag MMB (*p≤0.05, n=3 
in duplicates). This may be explained by the finding 
that SO-Mag MMB exhibited a higher velocity under a 
magnetic field compared to PEI-Mag MMB (19.10 ± 
0.69 µm/s vs. 11.40 ± 0.22 fA m2, respectively; Fig. 1d). 
This difference in magnetic potency became even 
more striking by calculation of the magnetic moments 
of the two MMB types, with SO-Mag MMB possessing 
an about three-fold higher magnetic moment than the 
PEI-Mag MMB (94.74 ± 0.47 fA m2 vs. 32.14 ± 0.12 fA 
m2, respectively; Fig. 1e). 
TABLE 1. Physical characteristics of MB with or without associated MNP (150 Fe µg/ml) or LV (5*108 VP/ml MMB). 
 LV Diameter [µm]a, b µg Fe/MMBb MNP/MMBb, c ζ Potential [mV]b 
naked MB - 5.0 ± 0.2 - - 6.2 ± 0.3 
pCHIV.eGFP + 1.9 *10-1 ± 0.8 *10-2 - - -8.8 ± 0.6 
SO-Mag MNP  - 4.0*10-2  ± 1.4*10-3 d   -16.1 ± 0.6 
SO-Mag MMB - 6.1 ± 0.1 * 2.0*10-8 ± 8.1*10-11 3.6*106 ± 2.5*10-4 3.9 ± 0.5 
 + 4.9 ± 0.5 4.4*10-8 ± 8.1*10-9 6.2*106 ± 1.2*10-6  # 5.0 ± 0.2 
PEI-Mag MNP - 2.8*10-2  ± 0.2*10-2 d - - 14.7 ± 1.2 
PEI-Mag MMB - 5.6 ± 0.2 * 2.5*10-8 ± 1.5*10-9 1.7*106 ± 4.6*10-4 9.6 ± 0.5 
 + 4.7 ± 0.2 6.8*10-8 ± 7.4*10-9 3.4*106 ± 2.4*10-5  # 9.4 ± 0.5 
a Particle diameter for MMB and lentivirus-MMB complexes, hydrodynamic diameter for sole pCHIV.eGFP LV; b Mean ± SEM; *p≤0.05 vs. naked MB, #p≤0.05 vs. MB+MNP, 
n=3 in duplicates; c MNP iron/particle content: 6.2*10-13µg Fe/SO-Mag MNP and 1.4*10-12µg Fe/PEI-Mag MNP; d adapted from Almstätter et al.15 
MNP: magnetic nanoparticles; MMB: magnetic microbubble; MB: microbubble; LV: lentivirus; Fe: iron. 
 
 
Figure 1. Characterization of MB containing SO-Mag or PEI-Mag MNP. (a) Lentivirus (3*108 VP/100µl MMB) binding to MMB was quantified by flow cytometry (mean ± SEM; 
*p≤0.05, n=3). (b) Representative dot plots of lentiviral pCHIV.eGFP particles and MMB solutions without (black) or with (green) associated lentivirus as assessed by flow 
cytometry. (c) Magnetizability of SO-Mag and PEI-Mag MMB coupled to GFP-lentivirus (1.5*108 VP/100 µl MMB) was assessed by exposing solutions to an external MF for 15 min 
with subsequent application of MMB-free supernatant and concentrated MMB to endothelial cell culture. Transduction rates (percentage of GFP expressing cells) were assessed 
by flow cytometry 72 h later (mean ± SEM; *p≤0.05, n=6). Panels show representative fluorescence images of GFP expression in cells. Scale bar indicates 500 µm. (d) Velocity 
measurements and (e) calculated magnetic moments of SO-Mag and PEI-Mag MMB solutions (150 µg Fe/ml). MB: microbubble, MMB: magnetic microbubble, LV: lentivirus, SSC: 
side scatter. 






Lentiviral SO-Mag MMB increase endothelial 
gene delivery by a caveolin-dependent 
endocytic mechanism 
To evaluate gene transfer efficiencies of SO-Mag 
MMB in dependence of the different technical 
parameters MF and US, SO-Mag MMB coated with a 
GFP expressing lentivirus were added to endothelial 
cell cultures following application of either a MF or 
US or combined treatment. Flow cytometry analysis 
of GFP expressing cells revealed that application of 
lentiviral SO-Mag MMB with US alone did not 
enhance transduction efficiency compared to sole 
lentiviral SO-Mag MMB application (Figs. 2a and b). 
In contrast, exposure to a MF resulted in a strong 
increase in transduction efficiency of SO-Mag 
lentiviral MMB (*p≤0.05, n=4). A cumulative effect of 
combined MF and US exposure after lentiviral 
SO-Mag MMB application on transduction efficiency 
could be observed compared to sole lentiviral SO-Mag 
MMB application (*p≤0.05, n=4). Although the same 
pattern was observed with PEI-Mag MMB, SO-Mag 
MMB possessed a significantly higher potency to 
deliver the GFP expressing lentivirus to endothelial 
cells in the combined setting (*p≤0.05, n=4). To 
identify the responsible mechanism of uptake 
relevant for lentiviral SO-Mag MMB-mediated gene 
delivery to endothelial cells, cells were treated with 
inhibitors of different endocytic pathways previous to 
SO-Mag MMB mediated transduction. Inhibition of 
caveolae-mediated endocytosis by 
methyl-β-cyclodextrin (MβCD), which extracts 
cholesterol from the plasma membrane16,17, was 
thereby shown to significantly decrease lentiviral 
uptake compared to cells without inhibitor treatment 
(Fig. 2c; *p≤0.05, n=5 in duplicates). In contrast, 
inhibition of phagosome-lysosome fusion by 
ammoniumchloride (NH4Cl) 18 or inhibition of the 
clathrin-mediated endocytic pathway by cytochalasin 
B (CytoB) 16 did not influence lentiviral SO-Mag 
MMB-mediated transduction (**p≤0.05, n=5 in 
duplicates). 
SO-Mag MMB improve targeted lentiviral gene 
delivery to vessels under flow conditions 
To evaluate the performance of the lentiviral 
MMB technique under flow conditions, endothelial 
cells cultured in channel slides were perfused with 
MMB coupled to a luciferase reporter lentivirus with 
simultaneous application of MF and US. As seen in 
Figure 3a, lentiviral MMB-mediated gene transfer 
under a shear rate of 1 dyn/cm2 resulted in a strong 
and local luciferase expression regardless of MNP 
type. However, the lentiviral PEI-Mag MMB showed 
reduced transduction efficiencies at increased shear 
rates of 5 and 7.5 dyn/cm², whereas the lentiviral 
SO-Mag MMB mediated transgene expression 
remained high under these conditions (*p≤0.05, 
**p≤0.01, n=4). Thereby, absence of US treatment 
significantly hampered luciferase expression 
compared to full treatment as seen in Figure 3b. 
Importantly, if only US without MF was applied, 
transgene expression was minimal, emphasizing the 
importance of magnetic attraction under flow 
conditions for successful gene delivery (**p≤0.01, 
n=4). Additionally, the use of lentivirus-MNP 
complexes without MB resulted in insufficient gene 
transfer (Fig. 3c; *p≤0.05, **p≤0.01, n=4). Thus, as the 
SO-Mag MMB were repeatedly found to possess 
functional advantages over PEI-Mag MMB, only these 
MMB were used in further experiments. In intact 
aortic segments we analysed the ability of the 
lentiviral MMB technique to locally transduce 
complete vessels under flow conditions using 
SO-Mag MMB carrying GFP expressing lentivirus and 
a recirculation setting at a mean shear rate of 7-8 
dyn/cm2, while MF and US were locally applied as 
depicted in Figure 3d. The resulting GFP expression 
was essentially localized in the region of MF and US 
application, as visualized by fluorescence microscopy 
of the whole aorta 72h after transduction (Fig. 3e). In 
aortas without MF and US targeting no transgene 
expression could be detected. Specific gene transfer to 
the endothelial cell layer could be verified by 
PECAM-1 co-staining of GFP expressing cells in cross 
sections of the treated aortas (Fig. 3f). GFP expression 
was thereby uniquely found in endothelial cells and 
not in other cell types of the vascular wall, such as 
vascular smooth muscle cells. 
LV-MMB mediated targeted gene delivery of 
VEGF to vessels enhances angiogenesis 
To test if the LV-MMB technique has potential 
for therapeutic use, we investigated whether SO-Mag 
MMB mediated targeted delivery of a lentiviral 
human (hu) VEGF expression vector to the 
endothelium of vessels has the ability to enhance 
vessel sprouting. Targeting of aortic endothelium was 
performed under flow using SO-Mag MMB coated 
with either huVEGF lentivirus or GFP lentivirus 
(huVEGF-MMB or GFP-MMB, respectively) by 
simultaneous application of a MF and US (see Fig. 3d). 
Aortas targeted with lentiviral huVEGF-MMB 
expressed high levels of human VEGF compared to 
aortas targeted with GFP-MMB as control (Fig. 4a; 
**p≤0.01, n=6). In addition, a 6-fold increase in 
secreted human VEGF was found in the supernatants 
of aortas targeted with lentiviral VEGF-MMB 
compared to GFP-MMB (Fig. 4b; *p≤0.05, n=6). 





Finally, targeted delivery of lentiviral VEGF-MMB 
enhanced the number of aortic vessel sprouts as well 
as the vessel sprouting area compared to targeted 
delivery of lentiviral GFP-MMB (*p≤0.05, n=6 aortas 




Figure 2. Biological properties of SO-Mag and PEI-Mag MMB in vitro. (a) 
Gene transfer efficiency of the lentiviral MMB technique using the two 
MMB types was assessed by MMB mediated transduction of endothelial 
cell culture. Single and combined parameters of the technique 
(GFP-lentivirus ± PEI-Mag/SO-Mag MMB ± MF ± US) were applied and 
transduction efficiencies were assessed by flow cytometry 72 h later 
(mean ± SEM; *p≤0.05 to full treatment with SO-Mag MMB, n=4 in 
duplicates). (b) Representative fluorescence images of GFP expression in 
cells. Lower panels: representative transmission (TM) light pictures. 
Scale bar indicates 500 µm. (c) Putative cellular uptake mechanisms 
underlying the lentiviral MMB technique were analysed by inhibiting 
caveolin-dependent endocytosis (Methyl-β-cyclodextrin, MβCD; 10 
mM), endosome-lysosome fusion (Ammoniumchloride, NH4Cl; 10 nM) 
or clathrin-dependent endocytosis (CytochalasinB, CytoB; 10 µM) prior 
to the application of the MMB technique and flow cytometry analysis of 
GFP expressing cells (mean ± SEM; *p≤0.05, n=4). MMB: magnetic 
microbubble, LV: lentivirus, US: ultrasound, MF: magnetic field. 






Figure 3. Targeted transduction of aortic endothelium under flow using lentiviral SO-Mag MMB. Gene transfer efficiency under flow was assessed (a) with SO-Mag and PEI-Mag 
MMB carrying luciferase expressing lentivirus under different shear rates (1, 5 and 7.5 dyn/cm2), (b) with and without MF and US targeting and (c) with lentiviral SO-Mag MNP 
complexes. Graphs show quantification of luciferase activity (mean ± SEM; *p≤0.05, n=4). Upper panels show representative bioluminescence images. (d) Schematic illustration 
of the MMB transduction setting applied to mouse aortas. SO-Mag MMB coated with GFP expressing lentivirus were added into a recirculation system applying a shear stress of 
around 7-8 dyn/cm². Simultaneously, US and MF were applied to locally accumulate and destroy the lentiviral MMB. (e) GFP expression in mouse aortas after SO-Mag MMB 
mediated lentiviral transduction with (right panels) and without (left panels) MF and US targeting was assessed by fluorescence microscopy of the whole aortas (n=3). Arrow 
indicates site of MF and US application. Scale bar indicates 1 mm. (f) Specific targeting of endothelial cells in aortas was verified by immunofluorescence staining of cross-sectional 
slices (n=3). Red: PECAM-1, green: GFP expression, blue: Hoechst nuclear stain. Scale bar indicates 10 µm. MMB: magnetic microbubble, LV: lentivirus, MF: magnetic field, US: 
ultrasound. 
 






Figure 4. SO-Mag MMB mediated lentiviral delivery of VEGF to vessels enhances angiogenesis. (a) SO-Mag MMB mediated targeting of huVEGF expressing lentivirus in mouse 
aortic endothelium ex vivo resulted in strong mRNA expression of huVEGF, as measured by qRT-PCR (mean ± SEM; **p≤0.01, n=6, house-keeping gene: murine 18S rRNA) and 
(b) enhanced secretion of huVEGF into the supernatant of these aortas, as assessed by ELISA, compared to GFP transduced aortas (mean ± SEM; **p≤0.01, n=6). As a result, an 
increased number of aortic sprouts (c) and a larger vascularized area around the aortic rings (d) was detected in VEGF transduced aortas compared to GFP transduced ones 
(mean ± SEM; *p≤0.05, n=6 aortas with 4 rings each). (e) Representative images of aortic rings expressing huVEGF or GFP by SO-Mag MMB mediated lentiviral gene delivery. 
Scale bar indicates 200 µm. 
 
Targeted lentiviral gene delivery in vivo upon 
systemic application of SO-Mag MMB 
To investigate if the lentiviral MMB technique is 
indeed applicable for in vivo gene targeting, SO-Mag 
MMB coated with luciferase expressing lentivirus 
were injected into the carotid artery of C57BL/6 wild 
type mice carrying a dorsal skinfold chamber (DSFC) 
19. Targeting of the lentiviral MMB to microvessels of 
the dorsal skin was accomplished by simultaneous 
application of a MF and US positioned on opposite 
sides of the DSFC window (see Fig. 5a). Eight days 
after lentiviral MMB targeting in vivo, mice showed a 
strong and local bioluminescence signal at the area of 
MF and US exposure (DSFC window) demonstrating 
successful delivery of the luciferase expressing 
lentivirus via SO-Mag MMB targeting (Fig. 5b; n=3). 
Lentiviral MMB injection without MF and US 
targeting, in contrast, did not result in an expression 
signal in the DSFC (Fig. 5b; n=3). Moreover, the 
number of integrated provirus copies in genomic 
DNA was significantly higher in the dorsal skin of 
mice receiving MF and US treatment upon injection of 
lentiviral SO-Mag MMB compared to dorsal skins of 
mice only receiving lentiviral SO-Mag MMB (Fig. 5c, 
p<0.05, n=3). Measurements of the MNP distribution 
in different organs 1 hour after MMB injection 
revealed the highest accumulation in the lungs and 
the liver (Fig. 5d; n=5). 96h after MMB injection, 
however, no MNPs could be detected indicating a 
clearance from the system and/or integration into the 
iron metabolism (n=4). As the lungs and the liver 
were identified as the major sites of MNP 
accumulation, these organs were also screened for 
integrated lentivirus copies. As seen in figure 5e, 
integrated provirus was also detected in the lungs and 
liver in mice receiving MF and US to the dorsal skin 
upon injection of SO-Mag MMB but to a significantly 
lower level compared to the dorsal skin (p<0.05, 
n=3-4). Importantly, whereas lentiviral MMB 
treatment without MF and US targeting caused 
relatively strong transgene expression in the lung and 





liver, targeting with MF and US to the dorsal skin 
upon lentiviral MMB injection reduced the transgene 
expression in the lungs (Fig. 5f, p=0.057, n=3) and 




Figure 5. SO-Mag MMB achieve targeted lentiviral delivery after systemic injection in vivo. (a) Schematic illustration of the in vivo setting applied for lentiviral MMB mediated gene 
delivery to the mouse dorsal skin. Left image: The observation window of the DSFC was centred between the tip of an electromagnet and the US transducer. MF and US were 
applied simultaneous to lentiviral MMB injection via the Arteria carotis catheter to achieve localized gene delivery. Right image: Intravascular lentiviral MMB accumulate at the site 
of MF and disrupt upon US application within the vessel. The triggered release of the lentiviral cargo results in enhanced local gene transfer to endothelial cells. (b) Representative 
bioluminescence images of the doral skinfold chamber in mice treated with luciferase expressing lentivirus coupled to MMB 8 days after application. Treatment with lentiviral 
MMB without targeting did not result in any transgene expression i.e. luciferase activity in the dorsal skin (left image), whereas targeted treatment with lentiviral MMB resulted 
in local luciferase activity in the targeted dorsal skin (right image). Bars next to images show quantification of bioluminescence signals (luciferase activity) in the dorsal skin in mice 
treated with lentiviral SO-Mag MMB with or without magnetic and ultrasound targeting (n=3). (c) Genomic provirus copy numbers/cell was higher in the dorsal skin of mice 
treated with MF and US after systemic injection of lentiviral SO-Mag MMB compared to no targeting (*p<0.05, n=3). (d) The MNP amount in different tissues was assessed using 
MPS 1h and 96h after injection respectively (n=5). (e) Integrated provirus copies/cell were in addition detected in lung and liver of mice receiving MF and US targeting to the dorsal 
skin but significantly less compared to the targeted dorsal skin (*p<0.05, n=3-4). (f) MF and US exposure after SO-Mag MMB injection reduced the transduction of secondary sites 
(lung and liver) compared to no targeting (*p<0.05, n=4). MMB: Magnetic microbubbles, MF: Magnetic Field, US: Ultrasound, DSFC: dorsal skinfold chamber. 
 






This study demonstrates that the lentiviral MMB 
technique improves site-directed vascular gene 
targeting to isolated vessels and to a vascular bed in 
vivo. For the first time, ultrasonic 
microbubble-mediated delivery1,3 and a magnetic 
nanoparticle (MNP)-assisted transport system20,21 
were combined with lentiviral gene delivery 
successfully generating a potent site-specific gene 
transfer system for in vivo applications.  
The use of MNP in combination with various 
genetic vectors (magnetofection method) has been 
object of several in vitro and in vivo studies by us 7, 8, 22, 
23 and other groups 15, 24, 25. However, gene targeting 
by MNP, especially after systemic administration in 
vivo, has proven to be insufficient probably due to low 
magnetic moments of the single MNP, particle 
aggregation in the blood, and rapid clearance from the 
circulation. The embedding of several MNP within 
the lipid monolayer of a MB, as studied here, has not 
only the advantage to reduce their biological 
clearance but also enormously increases the ability of 
site-specific targeting due to the increased magnetic 
moment of the MMB, which enables the MMB to 
withstand the forces of blood flow. Indeed, our single 
SO-Mag MMB exhibited a higher magnetic moment 
compared to the single SO-Mag MNP, which resulted 
in higher transduction efficiency under flow 
conditions. These data clearly demonstrate the 
superior magnetic properties of SO-Mag MMB as well 
as the supremacy of MMB over MNP-lentivirus 
complexes.  
The choice of the genetic vector with which a 
targeting system is combined is an important factor 
determining the success of the therapeutic 
intervention. Lentiviruses represent ideal vectors for 
the delivery of therapeutic genes to vascular 
endothelial cells, as they are capable of infecting even 
slow or non-dividing cells and enable permanent 
transgene expression due to stable genome 
integration26,27. Importantly, lentiviruses are already 
applied in clinical gene therapy28. Our results show 
that insufficient targeting of the naked lentivirus can 
be overcome by combining lentiviral gene transfer 
with MMB-mediated targeting. Of note, MMB 
generated with negatively charged SO-Mag MNP 
were surprisingly well capable of binding the 
negatively charged lentiviruses. This may be 
explained by the finding that the SO-Mag MMB 
complex actually exhibited a positive ζ potential. This 
finding is particularly important regarding future 
generation of new MNP, as it demonstrates the 
system to be independent of the surface charge of the 
MNP itself. Thus, focus can primarily be put on 
further improvement of magnetic properties. Our 
results strongly indicate that magnetic attraction of 
the lentiviral MMB towards the cell layer seems to be 
the main parameter determining the gene targeting 
efficiency of the method, as application of US alone 
did not increase the transduction efficiency to the 
same extent in our setting. US frequency and cycles 
per pulse have been shown to be of importance for 
improved MB gene delivery29 determining the degree 
of MB rupture and induction of cell permeability and 
our chosen settings may not be optimal for MB 
dependent transduction under static conditions. 
Under flow conditions, however, application of US in 
combination with MF is necessary to achieve even 
higher transduction rates. In fact, only combined 
treatment resulted in successful gene delivery in vivo, 
as shown in a previous study by us using MMB 
coated with pDNA9. This is probably not only due to 
the resulting release of the cargo but also to the 
destruction of the MB itself, which prevents the 
further circulation and thus distribution of the MMB 
leading to its concentration at the target site. 
Furthermore, MB sonication has been found to induce 
caveolae- and clathrin-dependent endocytosis in 
targeted cells29,30 thereby promoting uptake of i.a. 
viral particles31,32. Using our settings, we found 
transduction by lentiviral SO-Mag MMB to be 
mediated by caveolin-dependent endocytosis, 
potentially induced by sonication. We therefore 
hypothesize that the enhanced transduction efficiency 
of the MMB technique is the result of magnetic 
approximation between lentiviral MMB and cells and 
subsequent sonication-induced endocytosis.  
The successful targeting of aortic endothelium 
by lentiviral SO-Mag MMB under flow conditions 
indicates the power of this targeting approach. 
Importantly, the potency to achieve physiologically 
relevant effects was confirmed by the successful 
delivery of human VEGF expressing lentivirus to 
mouse aortic endothelium under flow conditions ex 
vivo, which resulted in increased huVEGF expression 
and secretion as well as aortic vessel sprouting. 
Therapeutic angiogenesis by gene therapeutic 
approaches has been attempted in a variety of clinical 
phase I/II studies facilitating pDNA11,14,33 or 
adenoviral vectors34,35, many of them with no or 
unsatisfactory results, potentially due to too low 
transgene expression36. In addition, successful vector 
delivery was only achieved by direct tissue injection 
or local catheter-application of the genetic vectors 13, 36, 
37. Therefore, an advanced intravascular targeting 
strategy, such as the lentiviral MMB technique, 
allowing for more efficient gene transfer, may 
constitute a valuable tool to achieve localized 
modulation of angiogenesis by targeted gene delivery 





of VEGF. Indeed, our data demonstrate the great 
potential of this technique for gene therapeutic 
angiogenesis. Most importantly, we successfully 
confirmed the functionality of lentiviral MMB as a 
vascular gene delivery system in vivo achieving 
lentiviral transgene expression at the target site. To a 
significantly lesser extent, secondary sites of reporter 
gene expression were found in the lung and liver 
probably due to remnant MMB being filtered through 
these organs containing extensive vascular networks. 
These were also the sites of the highest MNP 
accumulation, which may partly explain the off-target 
expression. Of note, targeting of the dorsal skin with 
MF and US reduced non-specific transgene expression 
to the lung and liver in contrast to mice receiving only 
lentiviral MMB without MF and US treatment. These 
observations certainly highlight the great advantage 
with this technique in reducing non-specific 
side-effects upon systemic application, which is of 
clinical importance. To further reduce undesired 
lentiviral transgene expression in other organs, 
further optimization of the lentiviral MMB technique 
using for instance viral shielding, which has been 
proven effective in previous studies with 
adenoviruses 38, may be necessary. Most importantly 
though, this is the first time relevant lentiviral gene 
transfer via the systemic circulation was successfully 
accomplished using combined magnetic and 
ultrasound targeting. Thus, our study highlights the 
huge potential of the lentiviral MMB technique as a 
tool for gene therapy, with a wide application 
spectrum, and at the same time creates the foundation 
for future therapeutic applications. 
Material and Methods 
Antibodies and Chemicals 
Rat PECAM-1 (#553370) was from BD Bioscience 
(Heidelberg, Germany). Alexa Fluor®555-labelled goat 
anti-rat antibody was from Life Technologies 
(Darmstadt, Germany). Collagenase A was from 
Roche (Mannheim, Germany). Luciferin was from 
Promega (Mannheim, Germany). All other chemicals 
were from Sigma-Aldrich (Taufkirchen, Germany). 
Lentiviral constructs 
Production of GFP-, luciferase- and 
huVEGF-expressing lentiviral particles has been 
described elsewhere39. Non integrating fluorescent 
labeled lentiviral particles pCHIV.eGFP were 
generated as described by Lampe et al.40. The physical 
viral titers (viral particles, VP) of lentiviral 
preparations were determined by reverse 
transcriptase activity measurements25 and biological 
titers (infectious particles) were determined by 
transduction of HEK293T cells and flow cytometry of 
transduced cells as described elsewhere39. 
Synthesis of magnetic nanoparticles 
Synthesis of core−shell type iron oxide MNP has 
been described elsewhere24. Surface modification 
protocols to generate PEI-Mag and SO-Mag MNP as 
well as further detailed characteristics of the used 
MNP have been described previously15,41. Iron 
concentrations of the MNP suspensions were 
determined spectrophotometrically with 
o-phenantroline as described previously24.  
Preparation and characterization of magnetic 
microbubbles and coating with lentiviral 
particles 
The phospholipid solution containing DPPE and 
DPPC (Lipoid) for production of magnetic 
microbubbles (MMB) was prepared as described 
elsewhere10. To generate a 150 and 250 µg Fe/ml 
MMB solutions, MNP (SO-Mag or PEI-Mag) 
corresponding to a total iron weight of 150 or 250 µg 
were added to 1 ml lipid solution in 1.5 ml glass vials 
with screw caps and silicon/PTFE membranes 
(Schubert & Weiss Omnilab GmbH, München, 
Germany). The mixtures were then covered with 
perfluorocarbon gas and shaken for 20s in a CapMix 
(3M ESPE, Seefeld, Germany). Lentiviral particles 
were added to the MMB solutions in an optimal 
VP:MNP25. In detail, 3.3*106 VP/µg Fe, corresponding 
to 5*108 VP/ml MMB solution, were added and left to 
associate for 10 min before use. Unless otherwise 
stated, amounts of lentiviral MMB applied in different 
cell culture experiments were individually calculated 
to achieve a cell:VP ratio of 1:5. Size and density of MB 
in solution with or without associated MNP (SO-Mag 
or PEI-Mag) and lentivirus (pCHIV.eGFP) were 
measured in 1:1000 dilutions in Hank’s balanced salt 
solution (HBSS; Biochrom, Berlin, Germany) using the 
Casy Counter (Schärfe Systems, Roche Diagnostics, 
Mannheim, Germany). From the resulting MMB 
concentrations (MB/ml) mean iron content (µg 
Fe/MMB) and MNP content (MNP/MMB) were 
calculated. ζ-potential of MMB in HBSS was 
measured by photon correlation spectroscopy using a 
Malvern 3000 HS Zetasizer (Malvern, Herrenberg, 
Germany). Magnetic moments were assessed by 
magnetic responsiveness measurements as described 
by Heidsieck42. Lentivirus binding was verified by 
flow cytometry analysis of pCHIV.eGFP-MMB using 
a FACS Canto II (BD Biosciences, Heidelberg, 
Germany). Magnetizability of MMB as well as 
lentivirus binding capacity was determined by 
exposing lentiviral MMB solutions to a magnetic field 
for 15 min and applying MMB-free supernatant as 





well as MMB concentrates to endothelial cell culture. 
Culture plates were subsequently placed over a 
neodymium iron boron magnet (IBA Bio TAGnology, 
Goettingen, Germany) for 30 min and exposed to 
ultrasound (30 s, 1 MHz, 2 W/cm2, 50% duty cycle) 
using an ultrasonic device from Rich-mar (G. 
Heinemann, Schwaebisch Gmuend, Germany). Cells 
were washed with PBS supplemented with calcium 
and provided with growth medium. GFP expression 
was detected 72 h later by fluorescence microscopy 
and flow cytometry.  
Cell culture 
Human umbilical vein endothelial cells 
(HUVEC) were purchased from PanBiotech 
(Aidenbach, Germany) and cultured in DMEM 
supplemented with 10% fetal calf serum, 1% 
Penicillin/Streptomycin and 50% complete 
EndoPAN3 medium (kit with 9 supplements; 
PanBiotech). All experiments with HUVEC were 
performed up to passage 5. 
Application of the lentiviral MMB technique 
under static conditions 
Medium on cells was exchanged by HBSS and 
lentiviral MMB corresponding to a multiplicity of 
infection of 5 were added. Lentiviral MMB were 
attracted to the bottom by placing the culture plate on 
top of a neodymium iron boron magnet and 
subsequent sonication (30 s, 1 MHz, 2 W/cm2, 50% 
duty cycle). Single method parameters (MMB, US, 
MF) were omitted to assess their contribution to the 
whole technique, otherwise the procedure was kept 
the same. To assess the endocytic mechanism relevant 
for lentiviral MMB-mediated gene delivery, HUVEC 
were treated with specific inhibitors (30 min) previous 
to SO-Mag MMB mediated transduction. 
Caveolae-mediated endocytosis was inhibited by 
incubation with 10 mM methyl-β-cxclodextrin 
(MβCD). Inhibition of phagosome-lysosome fusion 
was accomplished by incubation with 10 nM 
ammoniumchloride (NH4Cl) and 10 µM Cytochalasin 
B (CytoB) were used to inhibit the clathrin-mediated 
endocytic pathway. After lentiviral MMB treatment, 
cells were further incubated on the magnet for 30 min 
at 37°C. Cells were then rinsed with PBS 
supplemented with calcium and cultured in complete 
growth medium for another 72 h. GFP expression was 
assessed by fluorescence microscopy and flow 
cytometry. 
Application of the lentiviral MMB technique 
under flow in vitro 
HUVEC were grown to confluence on IBIDI 
µ-slides IV0.4 (Martinsried, Germany) and perfused 
with HBSS at shear rates of 1, 5 or 7.5 dyn/cm2 using a 
syringe pump (kdScientific, Holliston, MA, USA). 20 
µl of MMB or lipid-MNP mixture were preincubated 
with a luciferase-expressing lentivirus for 10 min, 
diluted 1:10 in HBSS and injected into the system. If 
indicated, US (30 s, 1 MHz, 2 W/cm2, 50% duty cycle) 
and MF were simultaneously applied to the cells. 
After further 2 min MF exposure under continued 
perfusion cells were incubated in complete growth 
medium for 72 h. Luciferase expression was assessed 
by application of 0.5 mg/ml luciferin using an IVIS 
imaging system from PerkinElmer (Waltham, MA, 
USA). Transduction efficiencies were quantified by 
measurement of pixel density using the Hokawo 
software (Hamamatsu Photonics, Hamamatsu City, 
Japan). 
Application of the lentiviral MMB technique 
under flow in isolated mouse aortas 
C57BL/6J wild type mice (Charles River, 
Burlington, MA, USA) were euthanized by cervical 
dislocation under anaesthesia (Midazolam 5 mg/kg; 
Medetomidin 0.5 mg/kg; Fentanyl 0.05 mg/kg). 
Thoracal aortas were isolated and intercostal arteries 
were cauterized to prevent leakage. Aortas were 
bilaterally catheterized and mounted above a magnet 
in a recirculation system constructed for 
MMB-mediated transduction (see Fig. 3e). Aortas 
(diameter ~1 mm) were perfused with serum-free 
DMEM at around 7-8 dyn/cm². 200 µl of LV-MMB 
(corresponding to 9.9*107 VP) were diluted 1:5 in 
HBSS and were slowly injected into the plastic tube 
upstream of the perfused aorta. US (120 s, 1 MHz, 2 
W/cm2, 50% duty cycle) was applied simultaneously 
at the site of magnetic field application. After further 
30 min of perfusion and MF exposure aortas were 
transferred to a cell culture dish with 5 ml of DMEM 
supplemented with 20% FCS and left for gene 
expression for 6 days in a humidified incubator before 
assaying. Aortic ring sprouting assays were 
performed as previously described43. 
Immunofluorescence staining of mouse aortas 
To assess localized transgene delivery by 
LV-MMB, GFP expression in whole mouse aortas was 
visualized by fluorescence microscopy. For 
immunofluorescence staining aortas were fixed for 1 h 
in 2% PFA, left in 20% sucrose over-night, embedded 
in OCT, and frozen at -80°C. Five µm cross-sectional 
slices were cut with a cryotome, blocked for 30 min 
with 5% BSA in PBS-T (0,1% Tween-20), and 
incubated with anti-PECAM-1 antibody (1:100 
dilution in PBS-T supplemented with 1% BSA) 
overnight. Sections were washed thrice with PBS-T 
and secondary antibody (1:500 dilution in PBS-T 





supplemented with1% BSA) was incubated for 2 h. 
After another three washing steps, the sections were 
incubated with Hoechst nuclear stain (50 µg/ml in 
PBS). The sections were then washed once more, and 
mounted under a coverslip. Fluorescence pictures 
were taken at 20-fold magnification (Leica DMI4000B, 
Leica Microsystems, Wetzlar, Germany). 
RNA isolation from mouse aortas and 
qRT-PCR 
Aortas transduced with huVEGF or GFP 
lentivirus-coated MMB were cultured in DMEM 
supplemented with 10% fetal calf serum, 1% 
penicillin/streptomycin and 50% complete 
EndoPAN3 medium for 24 h. Tissues were then 
mechanically ground in RNA lysis buffer and total 
RNA was isolated using the peqGOLD total RNA Kit 
(Peqlab). Quantitative reverse-transcriptase PCR 
(qRT-PCR) was performed using the TaqMan 
real-time PCR system (Applied Biosystems) as 
described before44. Primers and probes for human 
VEGF (fw: GCCTTGCTGCTCTACCTCCAC; rv: 
ATGATTCTGCCCTCCTCCTTCT; probe: 
AAGTGGTCCCAGGCTGCACCCAT, FAM) and 
murine 18S rRNA, as house-keeping gene, (NCBI 
Ref.Seq. X03205.1; #4310893E) were purchased from 
Applied Biosystems. 
Application of the lentiviral MMB technique in 
vivo 
All animal experiments were performed in 
accordance with the German animal protection law 
and approved by the district government of upper 
Bavaria (Regierung von Oberbayern, approval 
reference number AZ55.2-1-54-2532-36-2015). The 
study corresponds to the Guide for the Care and Use of 
Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, 
revised 1996). All surgical procedures were 
performed under deep anaesthesia achieved by i.p. 
injection of Midazolam (5 mg/kg body weight), 
Medetomidin (0.5 mg/kg body weight) and Fentanyl 
(0.05 mg/kg body weight) in 0.9% NaCl. The 
implantation of the dorsal skinfold chamber (DSFC) in 
16-24 week old C57BL/6J mice (Charles River, 
Sulzfeld, Germany) was performed as described 
before 45. The Arteria carotis of anaesthetized mice 
was catheterized the following day 45 and 100 µl of 
lentiviral MMB (250 µg Fe/ml; 8.3*107 VP/ml) were 
slowly injected with simultaneous application of a MF 
using an electromagnet (5min, 1.039 T) and US (30s, 2 
W/cm², 1 MHz, 50% duty cycle) from both sides of 
the DSFC window (see figure 5a). Afterwards, the 
catheter was removed and the skin incision was 
closed by suture. Anaesthesia was antagonized by s.c. 
injection of Flumazenil (0.5 mg/kg body weight) and 
Atipamezol (2.5 mg/kg body weight) in 0.9 % NaCl 
and postsurgical analgesia was provided by s.c. 
injection of 0.065 mg/kg body weight Buprenorphin 
with the first injection 10 min before injection of the 
antagonisation following administration in a 12 
hour-cycle until 3 days after lentiviral MMB 
application. 
Bioluminescence imaging 
To assess the systemic distribution of luciferase 
transgene expression resulting from lentiviral MMB 
transduction, luciferase activity was analysed 8 days 
after treatment. Mice were anaesthetized and luciferin 
was applied i.p. (100 µl, 3 mg/ml in 0.9% NaCl). 
Bioluminescence was detected using an IVIS imaging 
system from PerkinElmer (Waltham, MA, USA).  
DNA isolation from mouse tissue and 
quantification of proviral genome copy 
numbers 
Genomic DNA was extracted from mechanically 
homogenized tissues (dorsal skin tissue, livers and 
lungs) of mice receiving lentiviral MMB with or 
without MF and US targeting using the NucleoSpin® 
Tissue gDNA Kit (Macherey-Nagel). Provirus genome 
copy numbers per cell were assessed using the 
Lenti-X™ Provirus Quantitation Kit 
(Macherey-Nagel) following the manufacturer’s 
instructions. 
Detection of magnetic nanoparticles amounts 
in organs 
To determine the systemic distribution of MNP 
in lentiviral MMB treated mice, organs were isolated 
using non-metallic (iron-free) instruments, 
mechanically homogenized in PBS and exposed to 
magnetic particle spectroscopy (MPS) as described 
before 46. 
Statistical analysis 
All data are presented as means ± SEM. All 
statistical analyses were performed using Sigma Plot 
version 10.0. For multiple comparisons of normal 
distributed data the one-way analysis of variance 
(1-way ANOVA), followed by Student 
Newman-Keuls post-hoc test was performed. 
Differences were considered significant at an error 
probability level of p≤0.05. 
Abbreviations 
CytoB: cytochalasin B; DSFC: dorsal skinfold 
chamber; GFP: green fluorescent protein; LV: 
lentivirus; MB: microbubbles; MβCD: 
methyl-β-cxclodextrin; MF: magnetic field; MMB: 
magnetic microbubbles; MNP: magnetic 





nanoparticles; US: ultrasound; VEGF: vascular 
endothelial growth factor. 
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